Ignite Creation Date:
2024-05-05 @ 11:44 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00117143
Status:
COMPLETED
Last Update Posted:
2023-06-26
First Post:
2005-06-30
Brief Title:
Amgen Megakaryopoiesis Protein 2 AMG 531 in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura ITP
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
An Open-label Unit Dose-finding Study Evaluating the Safety and Efficacy of Amgen Megakaryopoiesis Protein 2 AMG 531 in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura ITP
Status:
COMPLETED
Status Verified Date:
2019-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the safety and tolerability of AMG 531 romiplostim a novel thrombopoiesis-stimulating peptibody and its effect on platelet counts in adults with immune thrombocytopenic purpura
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None